id: NEW:systemic_glycine_treatment_to_NEW:accumbal_glycine_levels
name: Systemic Glycine Treatment â†’ Nucleus Accumbens Glycine Levels
from_node:
  node_id: NEW:systemic_glycine_treatment
  node_name: Systemic Glycine Treatment
to_node:
  node_id: NEW:accumbal_glycine_levels
  node_name: Nucleus Accumbens Glycine Levels
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Systemic glycine administration (intraperitoneal) increases circulating glycine levels'
- 'Step 2: Glycine crosses the blood-brain barrier and enters central nervous system'
- 'Step 3: Extracellular glycine levels increase in the nucleus accumbens in a dose-dependent manner'
- 'Step 4: Elevated accumbal glycine acts on glycine receptors (GlyR) in the reward pathway'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Y. Olsson et al. 2020. "Effects of systemic glycine on accumbal glycine and dopamine
    levels and ethanol intake in male Wistar rats." https://doi.org/10.1007/s00702-020-02284-x
  supporting_citations:
  - Additional citations require full-text access - abstract references GlyT-1 inhibitor studies
  - Abstract references prior work on basal and ethanol-induced accumbal dopamine release involving GlyR
  - Abstract references repeated findings of GlyT-1 inhibitors decreasing ethanol intake in rats
  doi: 10.1007/s00702-020-02284-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Systemic glycine treatment increases extracellular glycine levels in the nucleus accumbens
  in a dose-dependent manner, providing a mechanism for modulating the dopamine reward pathway involved
  in alcohol use disorder.
moderators:
- name: glycine_dose
  direction: strengthens
  strength: strong
  description: Accumbal glycine levels increased in a dose-related manner with systemic glycine treatment
structural_competency:
  equity_implications: This mechanism supports pharmacological intervention development for AUD treatment,
    potentially expanding treatment options beyond current medications with modest effect sizes. Equitable
    access to such treatments would require addressing healthcare access disparities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.140200'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
